BRD2 Antibody (7C1B10) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-61716
Key Product Details
Species Reactivity
Human, Rat
Applications
ELISA, Flow Cytometry, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2B Clone # 7C1B10
Format
BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Purified recombinant fragment of human BRD2 (AA: 227-364) expressed in E. Coli.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Theoretical MW
88 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for BRD2 Antibody (7C1B10) - BSA Free
Western Blot: BRD2 Antibody (7C1B10)BSA Free [NBP2-61716]
Western Blot: BRD2 Antibody (7C1B10) [NBP2-61716] - Analysis using BRD2 mAb against HEK293 (1) and BRD2 (AA: 227-364)-hIgGFc transfected HEK293 (2) cell lysate.Flow Cytometry: BRD2 Antibody (7C1B10) - BSA Free [NBP2-61716]
Flow Cytometry: BRD2 Antibody (7C1B10) [NBP2-61716] - Analysis of Hela cells using BRD2 mouse mAb (green) and negative control (red).Western Blot: BRD2 Antibody (7C1B10)BSA Free [NBP2-61716]
Western Blot: BRD2 Antibody (7C1B10) [NBP2-61716] - Analysis using BRD2 mAb against human BRD2 (AA: 227-364) recombinant protein. (Expected MW is 40.6 kDa)Applications for BRD2 Antibody (7C1B10) - BSA Free
Application
Recommended Usage
ELISA
1:10000
Flow Cytometry
1:200-1:400
Western Blot
1:500-1:2000
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
PBS
Format
BSA Free
Preservative
0.05% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: BRD2
BRD2 and the other BET proteins have been implicated in a variety of diseases and pathologies. The BET proteins are known drivers of cancer through mutation and over-expression (1). Recently, in studies examining the role of Type 2 diabetes and obesity in breast cancer progression, the BET proteins have been shown to be critical regulators of metabolism and metastasis and are co-activators for the transcription of genes that encode pro-inflammatory cytokines in immune cells infiltrating the breast cancer microenvironment (1). Accordingly, knockdown of Brd2 in mice protected the animals from developing Type 2 diabetes and stopped the inflammatory response typically elicited by obesity (4). BRD2 is also highly expressed in the brain and the gene has been shown to play a role in juvenile myoclonic epilepsy, a common form of epilepsy that typically reveals itself during adolescence (5). In addition to the brain, BRD2 is highly expressed in the bone marrow and consequently its kinase activity has been shown to increase upon cellular proliferation and is significantly elevated in the peripheral blood lymphocytes of lymphoma patients (2, 3).
Research has been done to better understand protein interactions with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the novel coronavirus disease 2019 (COVID-19), as possible targets for drug therapies. It was recently described that that the transmembrane envelope protein (E) of SARS-CoV-2 binds to both BRD2 and BRD4, suggesting that bromodomain inhibitors could be a potential drug target (6). More specifically, the bromodomain inhibitors could be relevant regarding the secondary immune-related consequences that arise from SARS-CoV-2 infection (6). Bromodomain inhibitors are currently the focus of multiple clinical trials as a potential therapeutic in cancer and pulmonary arterial hypertension (6).
References
1. Andrieu, G.P., Shafran, J.S., Deeney, J.T., Bharadwaj, K.R., Rangarajan, A., & Denis, G.V. (2018). BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. J Leukoc Biol. https://doi:10.1002/JLB.5RI0917-380RR
2. BRD2 bromodomain 2 (human), NCBI
3. Taniguchi, Y. (2016). The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int J Mol Sci. https://doi:10.3390/ijms17111849
4. Wang, F., Deeney, J.T., & Denis, G.V. (2013). Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. Vitam Horm. https://doi:10.1016/B978-0-12-407766-9.00003-1
5. Gilsoul, M., Grisar, T., Delgado-Escueta, A.V., de Nijs, L., & Lakaye, B. (2019). Subtle Brain Developmental Abnormalities in the Pathogenesis of Juvenile Myoclonic Epilepsy. Front Cell Neurosci. https://doi:10.3389/fncel.2019.00433
6. Harrison, C. (2020). Drug researchers pursue new lines of attack against COVID-19. Nat Biotechnol. https://doi.org/10.1038/d41587-020-00013-z
Long Name
Bromodomain Containing 2
Alternate Names
FSRG1, RING3, RNF3
Gene Symbol
BRD2
Additional BRD2 Products
Product Documents for BRD2 Antibody (7C1B10) - BSA Free
Product Specific Notices for BRD2 Antibody (7C1B10) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...